Tendinopathy - Market Insight, Epidemiology, and Market Forecast - 2036

Tendinopathy Insights and Trends

• Tendinopathy is a common overuse tendon disorder characterized by activity-related pain, reduced function, and degenerative changes such as collagen disorganization and matrix breakdown. It commonly affects the Achilles, patellar, rotator cuff, and lateral elbow tendons and is primarily caused by failed tendon healing resulting from repetitive mechanical loading.
• Diagnosis is primarily clinical, based on load-related pain, localized tenderness, and functional impairment, supported by physical examination and provocation tests. Imaging (ultrasound and MRI) confirms structural changes but does not always correlate with symptom severity, making clinical assessment central.
• Treatment is mainly conservative, with progressive tendon-loading and eccentric exercise programs as first-line therapy. Physiotherapy, activity modification, and extracorporeal shockwave therapy (ESWT) are common adjuncts, while surgery is reserved for refractory cases.
• Pharmacologic treatments are mainly symptomatic: NSAIDs provide short-term pain relief, while corticosteroid injections may offer temporary benefit but have limited long-term efficacy and can weaken tendons. Platelet-rich plasma (PRP) is commonly used, but clinical outcomes remain inconsistent across studies.
• There is currently no approved disease-modifying therapy, creating a significant unmet need. Emerging approaches include PRP optimization, MSC-based therapies, and microRNA-based treatments (e.g., TenoMiR) aimed at restoring tendon structure and repair mechanisms.
• The market remains dominated by conservative and symptomatic management but is gradually shifting toward regenerative and mechanism-based therapies, driven by rising sports activity, occupational strain, and aging-related tendon degeneration.

DelveInsight's 'Tendinopathy- Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of tendinopathy, historical and forecasted epidemiology, as well as the Tendinopathy market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

The Tendinopathy market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Tendinopathy patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Tendinopathy and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Tendinopathy Market

High recurrence and chronic disease course

The condition frequently follows a persistent or recurrent trajectory, with many patients experiencing prolonged symptoms and functional limitation, especially in load-bearing tendons such as the Achilles and patellar tendons.

Strong association with physical activity and biomechanics

Incidence is highest in individuals exposed to repetitive loading, jumping, running, and overhead activities, with sports such as volleyball, basketball, tennis, and running showing consistently higher prevalence rates, reinforcing its role as a key sports medicine burden.

Degenerative nature and impaired tendon healing

Tendinopathy is now well-established as a failed healing / degenerative condition (tendinosis) characterized by collagen disorganization, matrix degradation, and reduced load tolerance, contributing to chronicity and incomplete recovery.

Tendinopathy Understanding and Treatment Algorithm

Tendinopathy Overview

Tendinopathy is a group of tendon disorders characterized by pain, functional limitation, and tendon degeneration, most often caused by repetitive mechanical overload and failed healing rather than acute inflammation. It commonly affects Achilles, patellar, rotator cuff, and lateral elbow tendons (tennis elbow) and is associated with sports and occupational overuse. The condition involves collagen disorganization and impaired tendon repair, leading to a predominantly degenerative, chronic course with persistent symptoms and reduced function.

Tendinopathy Diagnosis

Diagnosis of tendinopathy is primarily clinical, based on a detailed history of activity-related pain, typically worsened by repetitive loading or overuse, along with localized tenderness and functional impairment on physical examination. Pain is often reproducible with resisted movements or stretching of the involved tendon, supporting the diagnosis.

Imaging is used to confirm and assess severity, with ultrasound commonly identifying tendon thickening, hypoechogenicity, and neovascularization, while MRI provides a detailed evaluation of tendon degeneration, partial tears, and associated soft tissue changes, particularly in chronic or refractory cases. In most cases, diagnosis does not require laboratory testing, as tendinopathy is a non-systemic, degenerative condition, but investigations may be used to exclude inflammatory arthropathies or alternative causes of tendinopathy when clinically indicated.

Tendinopathy Treatment

Treatment of tendinopathy is primarily conservative and exercise-based, with load management and progressive tendon-loading programs (especially eccentric strengthening) forming the cornerstone of therapy to improve pain and function. NSAIDs (e.g., ibuprofen, naproxen, diclofenac) are used for short-term symptomatic relief, while corticosteroid injections may provide temporary benefit but are limited by high recurrence rates and potential tendon weakening.

Non-pharmacologic approaches, including physiotherapy, activity modification, shockwave therapy (ESWT), bracing, and cryotherapy, are widely used to support functional recovery and tendon adaptation. In refractory cases, biologic interventions such as PRP and autologous blood injections are considered, though evidence remains variable, while surgery is reserved for chronic, treatment-resistant disease.

Tendinopathy Unmet Needs

The section "unmet needs of tendinopathy" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Absence of disease-modifying therapies

2. Suboptimal and inconsistent treatment response

3. Diagnostic uncertainty and under-recognition

4. High recurrence and incomplete healing, and others.....

Tendinopathy Epidemiology

Key Findings from Tendinopathy Epidemiological Analysis and Forecast

• Tendinopathy is most frequently observed in physically active individuals and those exposed to repetitive mechanical loading, including athletes and manual labor populations, where it represents a major cause of overuse-related musculoskeletal injury.
• The condition is strongly associated with age-related tendon degeneration and cumulative mechanical stress, with increased occurrence in middle-aged and older adults, reflecting progressive decline in tendon repair capacity and structural integrity.
• As per secondary research, approximately 4.0% of Achilles tendinopathy patients progressed to rupture, highest in 50-59 years (4.3%) and 40-49 years (3.9%), significantly higher than in 20-39 and 60-69.
• Epidemiological data indicate that 898 per 100,000 individuals in the United States are diagnosed with Achilles tendinopathy, with the highest incidence observed in those aged 50-59 years, followed by the 40-49 year age group; both groups exhibit substantially higher rates than individuals aged 20-39 and 60-69 years.
• Overall, tendinopathy is slightly more common in males than in females. The difference is modest and mainly influenced by activity level and occupational load rather than sex alone.

Tendinopathy Drug Analysis & Competitive Landscape

The Tendinopathy drug chapter provides a detailed, market-focused review of the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the tendinopathy treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the tendinopathy therapeutics market.

Tendinopathy Pipeline Analysis

TenoMiR (CWT-001): Causeway Therapeutics

TenoMiR is a first-in-class investigational microRNA-based therapy developed by Causeway Therapeutics for tendinopathy, designed to target the underlying disease biology rather than symptoms alone. It is a synthetic mimic of microRNA-29a (miR-29a) intended to restore its reduced expression in injured tendon tissue and modulate key pathways involved in collagen regulation and tendon remodeling. The therapy is administered as a single, ultrasound-guided intratendinous injection, enabling localized delivery to the affected tendon site and targeted restoration of tendon homeostasis.

Tendinopathy Key Players, Market Leaders, and Emerging Companies

• Causeway Therapeutics and other

Tendinopathy Drug Updates

• In March 2026, Causeway Therapeutics announced presentation of data from its Phase II clinical trial evaluating TenoMiR in patients with lateral epicondylitis (tennis elbow).
• In October 2025, Causeway Therapeutics reported positive topline results from its Phase II clinical trial of TenoMiR. Although the primary pain endpoint was not met in the full analysis population, which included patients who did not receive the investigational therapy at the site of tendon injury.

Tendinopathy Market Outlook

The tendinopathy market is primarily symptom-driven, with current management focused on load modification, physiotherapy (eccentric loading), NSAIDs, and corticosteroid injections, which provide short-term pain relief but do not consistently reverse tendon degeneration. PRP and other biologic injections are increasingly used in practice, but show variable clinical outcomes due to heterogeneity in preparation and patient selection, while corticosteroids are limited by recurrence and potential adverse effects on tendon structure.

The competitive landscape is gradually shifting toward regenerative and mechanism-based therapies, including MSCs, microRNA-based approaches, and molecular pathway modulators, although these remain in early-stage development with no approved disease-modifying therapy currently available.

Overall, the market is expected to expand steadily, driven by high prevalence of sports and occupational-related injuries, aging populations, and rising demand for durable, non-opioid, and tissue repair-focused treatments, highlighting a clear unmet need for true tendon-regenerating therapies.

• According to the estimates, the United States accounted for the largest share of the Tendinopathy market among the major markets during the study period.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Tendinopathy (2022-2036 Forecast)

The tendinopathy treatment landscape comprises anti-inflammatory agents, corticosteroids, regenerative biologics, cell-based therapies, and emerging molecular pathway modulators, primarily aimed at reducing pain, modulating inflammation, and promoting tendon repair and remodeling rather than reversing structural degeneration.

• NSAIDs: Agents such as ibuprofen and naproxen reduce prostaglandin-mediated inflammation and pain signaling. These therapies are widely used for short-term symptomatic relief but do not modify underlying tendon pathology.
• miR-29a mimics: Emerging Agents such as TenoMiR regulate gene expression pathways involved in collagen synthesis and tendon matrix organization, targeting fundamental mechanisms of tendon degeneration and repair.

Tendinopathy Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the tendinopathy drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The tendinopathy treatment landscape is primarily driven by conservative care, with physiotherapy and structured load-management (eccentric and progressive tendon loading exercises) forming the first-line standard of care due to consistent improvements in pain and function. Overall, treatment remains largely non-disease-modifying, with injectable therapies used selectively and regenerative approaches still investigational, resulting in a landscape dominated by rehabilitation-based management and symptomatic relief strategies. Emerging therapies are expected to witness gradual uptake following maturation of clinical evidence and regulatory approvals, with adoption accelerating over time as real-world effectiveness data and clinician confidence increase.

Detailed insights of emerging therapies' drug uptake is included in the report.

Market Access and Reimbursement of Tendinopathy

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Tendinopathy Therapies Price Scenario & Trends

Pricing and analogue assessment of tendinopathy therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and the understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report....

Industry Experts and Physician Views for Tendinopathy

To keep up with tendinopathy market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the emerging tendinopathy therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in tendinopathy, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights at the country level. Centers such as the University of Pittsburgh, United States, and the University of Queensland, Australia, Kyushu University Hospital, Japan, etc., were contacted. Their opinion helps understand and validate current and emerging tendinopathy therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in tendinopathy.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis of tendinopathy, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are mainly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of tendinopathy, explaining its causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the tendinopathy market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM tendinopathy market.

Report Insights

• Tendinopathy Patient Population Forecast
• Tendinopathy Therapeutics Market Size
• Tendinopathy Pipeline Analysis
• Tendinopathy Market Size and Trends
• Tendinopathy Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Tendinopathy Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Tendinopathy Treatment Addressable Market (TAM)
• Tendinopathy Competitive Landscape
• Tendinopathy Major Companies Insights
• Tendinopathy Price Trends and Analogue Assessment
• Tendinopathy Therapies Drug Adoption/Uptake
• Tendinopathy Therapies Peak Patient Share Analysis

Report Assessment

• Tendinopathy Current Treatment Practices
• Tendinopathy Unmet Needs
• Tendinopathy Clinical Development Analysis
• Tendinopathy Emerging Drugs Product Profiles
• Tendinopathy Market Attractiveness
• Tendinopathy Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the tendinopathy market size, the market size by therapies, the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of tendinopathy?
• What are the disease risks, burdens, and unmet needs of tendinopathy? What will be the growth opportunities across the 7MM concerning the patient population with tendinopathy?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of tendinopathy? What are the current guidelines for treating tendinopathy in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the tendinopathy market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.